2nd Congress on Congenital Cytomegalovirus 2021

2nd Congress on Congenital Cytomegalovirus 2021

Format:8 videos + 1 pdf, size: 25.1 GB

Course Audience: pediatricians, infectious disease specialists, obstetricians/gynecologists

Overview:

CMV 2021 2nd Congress on Congenital CMV 21 – 22 OCTOBER 2021 Rome, Italy

Scientific Goal

The most prevalent congenital infection and the first cause of non genetic hearing loss continues to be largely ignored or misunderstood outside expert circles. We invite all care providers to attend this meeting to meet the experts and improve their practice for a better outcome.

Congress Topics

• The risks in pregnancy are well defined
• Screening and diagnostic tools are efficient, and quality control is effective
• Primary prevention is part of preconceptional medicine
• Vaccine technology has been revolutionized by the COVID pandemic
• Diagnosis is as reliable prenatally and postnatally
• Secondary and tertiary prevention are efficient and should be widely implemented
• Postnatal care has been simplified and rationalized
• Sensorineural hearing loss is not a fatality
• Are there any late complications other than hearing impairment is asymptomatic children?
• Sensorineural hearing loss is not a fatality
• Hearing rehabilitation in cCMV children with unilateral hearing loss
• Is there an association between CMV infections and ADD/Autism/Schizophrenia?
• Brain imaging for children with cCMV – Ultrasound or MRI?
• Universal screening for cCMV
• Early diagnosis of cCMV using Chorionic villus sampling
• Vestibular problems in symptomatic and asymptomatic cCMV
• What can we offer to asymptomatic children with late onset hearing loss?

The 2nd Congress on Congenital Cytomegalovirus 2021 was aimed at a diverse group of healthcare professionals involved in the care and research of congenital cytomegalovirus (CMV). The target audience included:

• Pediatricians
• Infectious Disease Specialists
• Obstetricians/Gynecologists
• Nurses and Nurse Practitioners
• Physician Assistants
• Researchers and Scientists in the field of CMV and related areas

This event provided a platform for these professionals to discuss the latest research, clinical practices, and advancements in the understanding and management of congenital CMV.

 

1 Welcome and SESSION 1 – Asymptomatic children with cCMV (Video MP4 Format)

2 Debate 1 UNIVERSAL NEONATAL SCREENING (Video MP4 Format)

3 SESSION 2 – Infection during pregnancy (Video MP4 Format)

4 DEBATE Vaccines – adults or toddlers (Video MP4 Format)

5 SESSION 4 Fetal infection (Video MP4 Format)

6 DEBATE Invasive Diagnosis the earlier the better (Video MP4 Format)

7 SESSION 5 – Hearing loss, vestibular disorders and rehabilitation in children with cCMV and Closing (Video MP4 Format)

8 Congenital CMV infection how to implement the diagnostics and the clinical follow up (Video MP4 Format)

Program (PDF Format)

 

* Detail:

21 October

09:00-09:05 WELCOME FROM CONGRESS PRESIDENTS Yves Ville, France

09:05-12:15 SESSION 1 – Asymptomatic children with cCMV Moderators: Daniel Blázquez Gamero, Spain – Efraim Bilavsky, Israel

09:05-09:25 What is an asymptomatic neonate in 2021? Daniel Blázquez Gamero, Spain

09:25-09:45 What can we offer to asymptomatic children with late onset hearing loss? Ina Foulon, Belgium

09:45-10:05 Advanced imaging in fetal CMV infection Chloe Arthuis, France

 10:05-10:15 Panel Discussion

10:15-10:25 (ID 11) – Does universal newborn screening for congenital cytomegalovirus (cCMV) infection help? A cohort study from Qatar and Germany Katrin Neumann, Germany

10:25-10:35 (ID 12) – Congenital CMV infection: a risk factor for neuro-psychological sequelae? Arianna Turriziani Colonna, Italy

10:35-10:45 (ID 48) – Congenital CMV infection – 7 years experience in a Portuguese neonatal intensive care unit Francisca Calheiros Trigo, Portugal

10:45-11:00 Discussion

11:00-11:30 COFFEE BREAK

11:30-11:40 (ID 16) Evolution of the intracranial features of congenital CMV in children Jack Garnham, United Kingdom

11:40-11:50 (ID 42) Single Nucleotide Polymorphisms of Interleukins and Toll-like Receptors and Neuroimaging Results in Newborns with Congenital HCMV Infection Justyna Czech-Kowalska, Poland

11:50-12:00 (ID 47) Newborns with Autism Spectrum Disorder: a link with congenital CMV? Perrine Coste Mazeau, France

12:00-12:15 Discussion

12:15-13:00 DEBATE: UNIVERSAL NEONATAL SCREENING Mark R. Schleiss, USA Vs. Daniel Blázquez Gamero, Spain

13:00-14:00 LUNCH / POSTER VIEWING

14:00-15:00 Congenital CMV infection: how to implement the diagnostics and the clinical follow up industry supported session

15:00-15:35 ORAL COMMUNICATION Congenital CMV infection

15:00-15:10 (ID 31) – Prevalence and Clinical Characteristics of Congenital Cytomegalovirus Infection in a Population-Based Universal Newborn Screening Study in Minnesota Mark Schleiss, United States

15:10-15:20 (ID 35) – Screening for congenital cytomegalovirus in preterm babies <30 weeks gestation Helen Payne, United Kingdom

15:20-15:35 Discussion

15:35-16:00 COFFEE BREAK

16:00-17:30 SESSION 2 – Infection during pregnancy Moderators: Tiziana Lazzaroto, Italy

16:00-16:20 Gestational age at maternal infection and postnatal outcome Christos Chatzakis, Greece

16:20-16:40 The biological clock for maternal serology is ticking for prenatal screening Marianne Leruez, France

16:40-17:00 Non-primary infections. Biological markers Daniele Lilleri, Italy

17:00-17:10 (ID 8) – Cytomegalovirus non primary infection during pregnancy: retrospective serological and molecular analysis in 38 patients. Claire Perillaud-Dubois, France

17:10-17:20 (ID 36) – CMV DNA in placentae from first trimester primary infection cases with or without fetal infection and with or without valaciclovir treatment Jacques Fourgeaud, France

17:20-17:30 Discussion

17:30-18:30 DEBATE: Vaccines – adults or toddlers? Yves Ville, France vs Efraim Bilavsky, Israel

22 October

09:00-12:00 SESSION 4 Fetal infection Moderators: Karl Oliver Kagan, Germany

09:00-09:20 International registry on the use of valaciclovir for secondary prevention Valentine Faure-Bardon, France

09:20-09:40 Hyperimmune globulins, how and how much Karl Oliver Kagan, Germany

09:40-10:00 Screening in pregnancy, what can you get for your money? Valérie Seror, France

10:00-10:20 Screening in pregnancy, why not then? Anna Gonce, Spain

10:20-10:45 Discussion

10:45-11:15 COFFEE BREAK

11:15-12:00 DEBATE: Invasive Diagnosis the earlier the better Yves Ville, France Vs. Schlomo Lipitz, Israel

12:00-12:20 Do we need to perform brain MRI in every infant with Ccmv? Efi Bilavsky, Israel

12:20-13:30 LUNCH AND POSTER VIEWING

13:30-16:15 SESSION 5 – Hearing loss, vestibular disorders and rehabilitation in children with cCMV Moderators: Ina Foulon, Belgium

13:00-13:20 Hearing loss in children with cCMV – from the broad spectrum to the individual Blake Papsin, Canada

13:20-13:40 How do we diagnose and treat vestibular problems in children with CCMV? Natacha Teissier, France

13:40-14:00 Hearing and vestibular rehabilitation in children with unilateral hearing loss Blake Papsin, Canada

14:00-14:15 Discussion

14:15-14:25 (ID 10) – The CONCERT Study: Treatment of Infants with Congenital Cytomegalovirus Infection and Isolated Hearing Loss, Detected Through Newborn Hearing Screening P.K. Chung, the Netherlands

14:25-14:35 (ID 4) – The effect of (val)ganciclovir on hearing in congenital cytomegalovirus: a systematic review. Elise De Cuyper, Belgium

14:35-14:45 (ID 40) – Immunogenicity Findings From a Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an mRNA- Based Vaccine Against Cytomegalovirus Infection Lori Panther, United States

14:45-14:55 (ID 43) – Universal newborn screening for congenital CMV infection: a prospective multicenter clinical trial Liliana Gabrielli, Italy

14:55-15:05 (ID 49) – Prognostic value of mild cerebral features in infected fetuses treated in utero after maternal infection in the first trimester N BOURGON, France

15:05-15:30 COFFEE BREAK

15:30-15:40 (ID 18) – Unmet needs in maternal diagnosis and treatment for congenital CMV in France: data from the French “congenital CMV declaration platform” of the National Reference Center for Herpesviruses Elodie Ribot, France

15:40-15:50 (ID 22) Cortical maturation assessed by magnetic resonance imaging in unaffected/mildly affected fetuses with cytomegalovirus infection. Ameth Hawkins-Villarreal, Spain

15:50-16:00 (ID 23) Performance of targeted congenital cytomegalovirus screening in newborns failing universal hearing screening: a multicenter study Jacques Fourgeaud, France

16:00-16:15 Discussion

16:15-16:45 Anti-CMV Vaccines. Any lesson learned from the Covid pandemic? Shilpe Sharma, Belgium

16:45-17:00 CLOSING REMARKS Yves Ville, Efraim Bilavsky